Venous Thrombosis in Multiple Sclerosis Patients after High-Dose Intravenous Methylprednisolone: The Preventive Effect of Enoxaparin by Kalanie, Hossein et al.
Hindawi Publishing Corporation
Thrombosis
Volume 2011, Article ID 785459, 4 pages
doi:10.1155/2011/785459
Research Article
VenousThrombosis in Multiple SclerosisPatients after
High-Dose Intravenous Methylprednisolone:The Preventive
Effectof Enoxaparin
HosseinKalanie,1 AliAminiHarandi,2 Shapoor Alidaei,1 DaryooshHeidari,3
SaeedShahbeigi,2 and Mehdi Ghorbani4
1Mehr Hospital, Shahid Beheshti University of Medical Sciences, Tehran 19857-17443, Iran
2Loghman Hospital, Shahid Beheshti University of Medical Sciences, Tehran 19857-17443, Iran
3Mehr Hospital, Shahid Beheshti University of Medical Sciences, Tehran 19857-17443, Iran
4Department of Cardiology, Faculty of Medicine Damascus University, P.O. Box 8487, Damascus, Syria
Correspondence should be addressed to Hossein Kalanie, hkalanie@yahoo.com
Received 16 August 2011; Revised 15 November 2011; Accepted 16 November 2011
Academic Editor: J. Harenberg
Copyright © 2011 Hossein Kalanie et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Aim. This study was designed to examine the possible role of high-dose intravenous methylprednisolone (IVMP) in the
development of venous thrombosis (VT). The cerebral one anecdotally had been reported in patients with relapsing remitting
multiple sclerosis (RRMS) in acute attacks and the possible preventive role of enoxaparin. Material and Methods.F r o map o o lo f
520patients,388patientswithdeﬁniteRRMSwhofulﬁlledentrycharacteristicswereselectedandrandomlyreceivedeithera5-day
courseofdaily1grIVMPortheaforementionedplus5daysofdailysubcutaneous40unitsofenoxaparinaccordingtoapredeﬁned
protocol. Results. Mean age, gender ratio, mean relapse rate, and EDSS were similar in both groups of patients (P > 0.05). Finally,
366 patients remained in the study. Of 188 patients treated with IVMP with 855 relapses, 5 developed VT (0.37% per patient per
year and 0.58% per each course of IVMP) within 3 to 15 days of starting therapy. None of the 178 patients who experienced 809
relapses who received IVMP plus enoxaparin developed such complications. Conclusion. The study implies that high-dose IVMP
in MS exacerbation may increase the risk of VT and prophylactic anticoagulant treatment in this setting is warranted.
1.Introduction
Intravenous corticosteroid (CS) is a well-deﬁned treatment
for multiple sclerosis (MS) relapses and high doses of meth-
ylprednisolone (MP) (bolus of 500–1000mg of MP daily for
3 to 5 days followed or not by oral prednisolone), routinely
delivered in many neurological centers with good tolerance
[1,2].Anecdotalreportlinkedhigh-doseCStreatmentinMS
to an increased risk of developing cerebral venous thrombo-
sis (CVT) [3, 4]. We also observed now and then MS patients
in relapses who developed deep vein thrombosis (DVT)
in their lower extremities during perfusion of high-dose
MP. Because high doses of intravenous methylprednisolone
(IVMP) are routinely delivered in a wide variety of other
neurological and medical disorders, such an association may
have an impact on prophylactic strategies against venous
thromboembolism during such a treatment. In this study,
we tried to examine the possible role of high-dose IVMP
in the development of venous thrombosis in RRMS patients
in acute relapse and evaluate the possible preventive eﬀect
of daily subcutaneous enoxaparin (low-molecular-weight
heparin) on this life threatening side eﬀect.
2.MaterialandMethod
The study took place at Mehr Hospital, Tehran, Iran. The
study period was from March 2002 to April 2009. Searching
the clinical ﬁles of 520 Caucasian Iranian patients attending
our MS clinic [5] with clinically deﬁnite MS, according to
thecriteriaofMcDonald[6],380casesofrelapsing-remitting2 Thrombosis
type (RRMS) who fulﬁlled the inclusion criteria were
selected. These criteria consisted of an age range between
14 and 45 years, a Kurtzke Expanded Disability Status Score
(EDSS)[7]notover4.Exclusioncriteriawereincludingovert
diabetes or obesity, CS therapy or contraceptive use for at
least 12 months, history of previous venous thrombosis or
cigarette smoking, positive pregnancy test, abnormal hae-
mostatic parameters (serum ﬁbrinogen, antithrombin III,
C and S protein, absence of resistance to activated C
protein due to factor V leiden mutation), and positive
Anticardiolipin (IgG and IgM) antibodies. Also all patients
with other clinical conditions that could potentially cause
the neurological clinical and/or other laboratory ﬁndings
were excluded (e.g., Lupus erythematosus, Behcet’s disease,
Sjogren disease, vasculitis, HIV infection, syphilis, human T-
cellleukemia/lymphomavirus(HTLV1and2),andcerebral
autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy). Written informed consent was
obtained from all patients before participating in study.
Patients then were assigned to a serial list of random num-
bers. Odds were assigned to receive a 5-day course of daily
1gr IVMP following an exacerbation event. Evens received
the above-mentioned drug plus daily 40mg subcutaneous
enoxaparin.
Gastroduodenal protection was achieved by using 20mg
ofomeprazolecapsuledailyduringthestudyperiod.Patients
were advised to call the hospital in the event of any neuro-
logical symptoms or disability. In such cases, the assessing
physician examined the patient to conﬁrm a possible relapse
and if so admitted the patient to the hospital to receive
the above-mentioned therapy. An MS exacerbation was
deﬁned as either the onset of new symptoms and signs
or deterioration in the existing symptoms and signs of
at least 24 hours in duration without concomitant fever,
accompanied by documented change in the neurological
examination. A change of 1.0 or greater in the EDSS grading
was considered signiﬁcant [8]. Upon admission and before
beginning therapy, all patients had a chest X-ray, complete
blood count, electrolytes, BUN, serum: creatinine, aspar-
tate aminotransferase (SGOT), alanine aminotransferase
(SGPT), alkaline phosphatase, bilirubin, glucose, urinalysis,
intermediate strength puriﬁed protein derivative skin test for
tuberculosis, and pregnancy test if appropriate [9]. Patients
were advised to be up and about between infusions to reduce
the possible eﬀect of immobility. Patients were monitored
before and during the treatment course and were reviewed
every week for the ﬁrst 4 weeks and then every 3 months as
a routine followup. If there was any sign referable to DVT
such as pain or swelling of legs or CNS involvement such
as headaches, vomiting, focal signs, they underwent duplex
sonography or brain MR venography, respectively. Paired-
sample t-test and independent sample t-test were statistical
methods used.
3. Results
Of 380 patients having clinically deﬁnite RRMS according to
McDonald’s criteria, 14 dropped out of the study not being
Table 1: Entry characteristics (mean ± SD) of patients.
∗IVMP ∗∗IVMP + SCE
Patients 188 178
Age 29.4 ±7.12 9 .8 ±7.2
Sex 2.2:1 2.2:1
Gender Ratio F:M 2.2:1 2.2:1
Mean Annual Relapse Rate 0.65 0.65
EDSS 3.4 ±0.50 3.4 ±0.82
∗Intravenous methylprednisolone.
∗∗IVMP + subcutaneous enoxaparin.
EDSS: the Expanded Disability Status Scale.
able to follow the protocol (2 had plan for pregnancy, 4
started on contraceptive pills, and 6 missed their followup),
188 were treated with IVMP, and 178 treated with IVMP plus
subcutaneous enoxaparin following an exacerbation event.
Entry characteristics of patients are summarized in Table 1.
Mean age, gender ration, mean annual relapse rate, and
EDSS were similar in both groups of patients (P>0.05).
Of 188 patients who received only IVMP (130 female and
58 male) with a total of 855 relapses, 5 developed venous
thrombosis (0.37% per patient per year and 0.58% per each
course of IVMP).
Two females aged 32, 37 and one male aged 39 had DVT
involvinglowerextremities;2happenedatday7and10inthe
ﬁrstcourse,1atday10inthesecondcourse,respectively,and
another 2 females aged 35 and 39 developed CVT involving
the left sigmoid and sagittal sinuses, respectively, at days 5
and 15 during the ﬁrst and ﬁfth course of therapy (Table 2).
Of 178 patients who received IVMP plus subcutaneous
enoxaparin (124 females and 54 males) with 809 relapses,
none had signs of VT.
Using Fisher’s Exact Test to compare thrombotic event
between two groups, a P v a l u eo f0 . 0 6 1w a so b t a i n e d
(5 thrombotic patients in 188 of MS patients) and 0 (0
thrombotic patients in 178 of MS patients, P = 0.061).
4. Discussion
Both DVT and CVT have some known predisposing and
etiologicfactors.ForDVT,theyarereducedmobility,obesity,
malignant disease, history of venous thromboembolism,
thombophilic disorders, and older age [10]. CVT although
a rare condition induced by multiple etiologies including
infectiousdisease,inﬂammatorydiseases(insomecasesanti-
coagulants and CS are associated in their treatment), puer-
periumandpregnancy,braintumorandtrauma,coagulation
abnormalities, neoplasic disease, and drugs [11, 12]. Despite
the diversity of cause, the etiology of cerebral venous throm-
bosis remains undetermined in 20–30% of the cases [13, 14].
Drugs can play as a predisposing factor in both conditions.
One of the medications which have been under suspicion in
this respect, especially CVT, is the use of high-dose IVMP
in treating MS patients in acute relapse. In a cohort of
120 consecutive patients with acute CVT, diagnosed either
by digital subtraction angiography or magnetic resonance
imaging and MR angiography, 4 patients who developedThrombosis 3
Table 2: Characteristic of patients on high-dose IVMP with venous thrombosis.
Sex Age Course number Day of diagnosis Involved site Type of thrombosis
1F 3 2 1 7 L e f t l e g ∗DVT
2F 3 7 1 1 0 L e f t l e g D V T
3M 3 9 2 1 0 B o t h l e g s D V T
4F 3 5 1 5 L e f t s i g m o i d ∗∗CVT
5 F 39 5 15 Sagittal Sinus CVT
∗DVT: deep vein thrombosis.
∗∗CVT: cerebral vein thrombosis.
CVT during intravenous CS treatment (≥500mg/day over
5 days) for a relapse of MS were identiﬁed along with 2
more cases who received high-dose CS for treatment of optic
neuritis [15]. Overall, this amounts to 5% of patients who
developed CVT during CS treatment, a rate as high as could
beexpectedinproteinCorSdeﬁciency[16].Acausativelink
also has been proposed between lumbar puncture (LP) and
CVT but it was not always the case [17]. In most instances,
LP played its role whenever other predisposing factors such
as high-dose CS use is in action [13, 14, 18, 19].
High-dose IVMP for 3–5 days is frequently used for
rapid and strong immunosuppression in acute autoimmune
disease and in transplantation medicine. Glucocorticoids are
commonly thought to be procoagulant increasing the risk
of thromboembolic complications like DVT and pulmonary
embolism [20–22]. The acute femoral head osteonecrosis
occurring during or after high-dose steroid treatment also
may be explained by hypercoagulopathic mechanisem [23].
Cushing syndrome features high-glucocorticoid secretion
and associated hypercoagulable state often involves an
increase in Von Willebrand factors [24]. Glucocorticoids
usage especially at high doses is complicated by adverse out-
come such as thrombotic events in condition like myeloma
and osteoporosis [25]. However, hypercoagulopathy induced
by high-dose IVMP is a controversial issue. In one study
investigating the eﬀect of high-dose IVMP on sensitive
markers of coagulation and ﬁbrinolysis activation, authors
did not ﬁnd evidence for a pronounced acute prothrombotic
state induced by this medication [26] and pointed the role
of underlying disease for an elevated thrombolytic risk. An-
ecdotal reports in recent years may suggest that MS per se
may provide a suitable background for VT [17, 24, 27].
In this study, we tried to examine the possible role of
high-dose IVMP in the genesis of venous thrombosis while
excluding almost all known possible predisposing factors
including poor mobility during treatment of acute relapses
in RRMS. This study implies that VT can occur with an
estimated incidence of 0.58% during any course of IVMP
while treating an MS relapses even in the absence of other
riskfactorsandprophylacticenoxaparincanpreventthisside
eﬀect.
Interestingly enough 4 out of our 5 patients are above
35 years of age and 4 of them are female which may denote
the role of age and gender as predisposing factors in our
patients. In fact, estrogens have many diﬀerent eﬀects on the
coagulation system. These include increases in the level of
procoagulant factors VII, X, XII, and XIII and reductions in
the anticoagulant factors protein S and antithrombin [28].
T h es t u d yw a sd o n eo ns m a l ls c a l ea n di fw eh a d2 8 0
subjects in each group, on the basis of power statistical
calculation with β = 20%, we would have a P value of 0.05
which is a warning. Taken together, we believe that there
is a synergistic eﬀect between high-dose IVMP and MS. In
fact, when IVMP acts on MS immunopathology, they may
then provide a suitable background for occurrence of VT.
In this setting LP by its own mechanism [29] may have a
compounding eﬀect. Since we tried to discard susceptible
patients for thrombosis, the ﬁnal rate of this side eﬀect
might have been much higher in general population of MS
therefore prophylactic treatment with enoxaparin may be
warranted in these patients.
We would like to emphasize that our study is done on
a limited number population with its own speciﬁc genetic,
environmental, and cultural background [30], and perhaps
the results cannot be extended with certainty to other
MS populations of other nations. Therefore, similar studies
in a larger scale on other ethnic population on diﬀerent
continents are warranted and if it conﬁrms our hypothesis,
it could to save life of many patients by a reasonable pro-
phylactictherapy.Inthatcase,whateverthecosteﬀectiveness
may be, the high mortality rate of CVT and the danger of
pulmonary emboli from DVT will make it negligible.
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